Compare SBSI & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBSI | INBX |
|---|---|---|
| Founded | 1960 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 999.7M |
| IPO Year | 1995 | 2024 |
| Metric | SBSI | INBX |
|---|---|---|
| Price | $32.90 | $103.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $35.33 | ★ $150.00 |
| AVG Volume (30 Days) | 64.3K | ★ 442.3K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $28.87 | N/A |
| Revenue Next Year | $5.82 | N/A |
| P/E Ratio | $42.19 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $26.32 | $12.80 |
| 52 Week High | $34.53 | $155.29 |
| Indicator | SBSI | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 45.50 |
| Support Level | $31.73 | $99.20 |
| Resistance Level | $34.06 | $153.14 |
| Average True Range (ATR) | 0.69 | 11.61 |
| MACD | 0.01 | -3.13 |
| Stochastic Oscillator | 70.31 | 7.41 |
Southside Bancshares Inc is a bank holding company. Through its subsidiary, it operates as a financial institution offering various financial services to individuals, businesses, municipal entities, and nonprofit organizations. These services include consumer and commercial loans, deposit accounts, wealth management and trust services, brokerage services, and safe deposit services. The company's primary market areas are East Texas, Southeast Texas, and the greater Dallas-Fort Worth, Austin, and Houston, Texas.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.